Arcadia Biosciences Stock Today

RKDA Stock  USD 4.37  0.00  0.00%   

Performance

OK

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
Arcadia Biosciences is trading at 4.37 as of the 24th of July 2025, a No Change since the beginning of the trading day. The stock's open price was 4.369. Arcadia Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain
Food, Beverage & Tobacco
IPO Date
15th of May 2015
Category
Consumer Defensive
Classification
Consumer Staples
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company was incorporated in 2002 and is headquartered in Davis, California. Arcadia Bio operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. The company has 1.37 M outstanding shares of which 23.04 K shares are at this time shorted by private and institutional investors with about 1.44 trading days to cover. More on Arcadia Biosciences

Moving together with Arcadia Stock

  0.82PM Philip Morris InternPairCorr
  0.69BTI British American Tobacco Earnings Call This WeekPairCorr

Moving against Arcadia Stock

  0.85PAVS Paranovus EntertainmentPairCorr
  0.8TSN Tyson Foods Sell-off TrendPairCorr
  0.78CCU Compania Cervecerias Earnings Call This WeekPairCorr
  0.77TAP Molson Coors BrewingPairCorr
  0.67STZ Constellation BrandsPairCorr
  0.65SAM Boston BeerPairCorr

Arcadia Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentStanley Jacot
Thematic Ideas
(View all Themes)
Business ConcentrationAgricultural Products & Services, Food, Beverage & Tobacco, Consumer Defensive, NASDAQ Composite, NASDAQ Composite Total, Natural Foods, Processed Foods, Agriculture, Consumer Staples, Food Products, Agricultural Inputs, Basic Materials (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.280.3732
Way Down
Slightly volatile
Total Current LiabilitiesM2.6 M
Way Up
Pretty Stable
Non Current Liabilities Total4.5 M4.7 M
Notably Down
Slightly volatile
Total Assets24.9 M13.5 M
Way Up
Pretty Stable
Total Current Assets8.8 M9.2 M
Notably Down
Pretty Stable
Debt Levels
Arcadia Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcadia Biosciences' financial leverage. It provides some insight into what part of Arcadia Biosciences' total assets is financed by creditors.
Liquidity
Arcadia Biosciences currently holds 155 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Arcadia Biosciences has a current ratio of 6.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Arcadia Biosciences' use of debt, we should always consider it together with its cash and equity.

Change To Inventory

161,700
Arcadia Biosciences (RKDA) is traded on NASDAQ Exchange in USA. It is located in 5950 Sherry Lane, Dallas, TX, United States, 75225 and employs 9 people. Arcadia Biosciences is listed under Agricultural Products & Services category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.89 M. Arcadia Biosciences conducts business under Food Products sector and is part of Consumer Staples industry. The entity has 1.37 M outstanding shares of which 23.04 K shares are at this time shorted by private and institutional investors with about 1.44 trading days to cover. Arcadia Biosciences currently holds about 21.23 M in cash with (9.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96.
Check Arcadia Biosciences Probability Of Bankruptcy
Ownership Allocation
Almost 93.59 percent of Arcadia Biosciences outstanding shares are held by general public with 0.82 (percent) owned by insiders and only 5.59 % by other corporate entities.
Check Arcadia Ownership Details

Arcadia Stock Institutional Holders

InstituionRecorded OnShares
Genworth Financial Wealth Mgmt Inc2025-03-31
5.0
Harbour Investments, Inc.2025-03-31
1.0
Larson Financial Group, Llc2025-03-31
1.0
Northern Trust Investments N A2024-12-31
0.0
U.s. Bancorp2024-12-31
0.0
Oliver Lagore Vanvalin Investment Group2024-12-31
0.0
Advisor Group Holdings, Inc.2025-03-31
0.0
Mariner Wealth Advisors Llc2025-03-31
27.5 K
Vanguard Group Inc2025-03-31
14 K
Geode Capital Management, Llc2025-03-31
12.8 K
State Street Corp2025-03-31
12.1 K
View Arcadia Biosciences Diagnostics

Arcadia Biosciences Historical Income Statement

At present, Arcadia Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 6 M, whereas Depreciation And Amortization is forecasted to decline to about 107.3 K. View More Fundamentals

Arcadia Stock Against Markets

Arcadia Biosciences Corporate Management

When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.285
Earnings Share
(0.57)
Revenue Per Share
3.854
Quarterly Revenue Growth
0.216
Return On Assets
(0.31)
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.